OH2 Injection in Solid Tumors

This study tests OH2, a modified herpes virus injected directly into tumors, to treat a variety of advanced solid cancers including breast cancer, gastrointestinal cancers, liver cancer, cervical cancer, melanoma, head and neck cancers, and soft tissue sarcoma. The virus is designed to infect and kill cancer cells while also stimulating the immune system. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed advanced (stage III or IV) cancer of one of the target types that has not responded to standard treatment - You have at least one tumor that can be injected directly - Your overall health is reasonably good (ECOG 0-1) and your expected survival is more than 3 months - Your blood counts and major organ functions are within acceptable ranges **You may NOT be eligible if...** - You have uncontrolled brain metastases - You have active herpes sores in the genital area (must wait at least 3 months after resolution) - You are pregnant or breastfeeding - You have severe uncontrolled medical conditions such as uncontrolled diabetes, uncontrolled high blood pressure, or active autoimmune disease - You have had another cancer in the past 3 years - You are allergic to herpes virus or any ingredients in the study drug Talk to your doctor to see if this trial is right for you.